Jim Simons Essa Pharma Inc. Transaction History

Renaissance Technologies LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$2.74 - $7.35 $66,401 - $178,119	24,234 New	24,234 $160,000
Q4 2022 Feb 13, 2023	SELL	$1.5 - $4.82 $226,929 - $729,198	-151,286 Reduced 81.38%	34,624 $87,000
Q3 2022 Nov 14, 2022	BUY	$1.75 - $3.44 $280,542 - $551,466	160,310 Added 626.21%	185,910 $338,000
Q2 2022 Aug 12, 2022	BUY	$3.15 - $7.94 $80,640 - $203,264	25,600 New	25,600 $81,000
Q4 2021 Feb 11, 2022	SELL	$7.8 - $14.38 $1.1 Million - $2.03 Million	-141,500 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$7.76 - $29.37 $945,168 - $3.58 Million	121,800 Added 618.27%	141,500 $1.13 Million
Q2 2021 Aug 13, 2021	SELL	$24.17 - $34.28 $1.35 Million - $1.91 Million	-55,800 Reduced 73.91%	19,700 $563,000
Q1 2021 May 13, 2021	BUY	$11.61 - $32.08 $147,412 - $407,319	12,697 Added 20.22%	75,500 $2.19 Million
Q4 2020 Feb 10, 2021	SELL	$5.47 - $12.1 $158,613 - $350,863	-28,997 Reduced 31.59%	62,803 $749,000
Q3 2020 Nov 13, 2020	BUY	$6.0 - $7.79 $324,138 - $420,839	54,023 Added 143.01%	91,800 $633,000
Q2 2020 Aug 13, 2020	BUY	$3.71 - $6.2 $140,152 - $234,217	37,777 New	37,777 $234,000
Q1 2020 May 14, 2020	SELL	$3.23 - $5.87 $41,385 - $75,212	-12,813 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$3.05 - $6.0 $39,079 - $76,878	12,813 New	12,813 $70,000

35.1M

15.8K

21K

Ticker EPIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,073,100
Market Cap $72.3M
Description
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreem...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.